-
Phase 1/Phase 2
-
-
18+Age Range
-
Active, Not Recruiting
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
You're about to leave bmsclinicaltrials.com
This link takes you to a website of Bristol Myers Squibb that may have a different purpose, may have different terms and conditions, and is being provided solely to enable you to contact Bristol Myers Squibb.
You're about to leave bmsclinicaltrials.com
This link takes you to a website of Bristol Myers Squibb that may have a different purpose, may have different terms and conditions, and is being provided solely to enable you to contact Bristol Myers Squibb.
You are about to leave bmsclinicaltrials.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
You are about to leave bmsclinicaltrials.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
You are about to leave bmsclinicaltrials.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
You are about to leave bmsclinicaltrials.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
You are about to leave bmsclinicaltrials.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
Active, Not Recruiting
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
The purpose of this study is to assess the safety, tolerability, and efficacy of
BMS-986158 alone and in combination with either Ruxolitinib or Fedratinib in participants
with Dynamic International Prognostic Scoring System (DIPSS)-intermediate or high risk
blood cancer. Part 1 consists of BMS-986158 in combination with either Ruxolitinib or
Fedratinib and P...Read More
art 2 consists of BMS-986158 in combination with either Ruxolitinib or
Fedratinib and BMS-986158 alone.Read Less
Experimental: Part 1A: BMS-986158 + Ruxolitinib
Experimental: Part 1B: BMS-986158 + Fedratinib
Experimental: Part 2A1: BMS-986158 + Ruxolitinib
Experimental: Part 2A2 Add-On: BMS-986158 + Ruxolitinib
Experimental: Part 2A3: BMS-986158 + Ruxolitinib
Experimental: Part 2B1: BMS-986158 + Fedratinib
Experimental: Part 2B2: BMS-986158 Mono and/or (BMS-986158 + Fedratinib), if applicable